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Abstract
Cyclin D1 is over-expressed in various human tumors and therefore can be a potential oncogenic target antigen. However,
only a limited number of T cell epitopes has been characterized. We aimed at identifying human cyclin D1-derived peptides
that include both CD4 and CD8 T cell epitopes and to test if such multi-epitope peptides could yield improved cytotoxic
CD8 T cell responses as well as cytotoxic CD4 T cells. Five HLA-DR.B1-binding peptides containing multiple overlapping CD4
epitopes and HLA-A0201-restricted CD8 T cell epitopes were predicted by computer algorithms. Immunogenicity of the
synthetic peptides was assessed by stimulating T cells from healthy donors in vitro and the epitope recognition was
measured by IFN-c ELISPOT and
51Chromium release assays. A HLA-DR.B1 peptide, designed ‘‘DR-1’’, in which a HLA-A0201-
binding epitopes (D1-1) was imbedded, induced CD3 T cell responses against both DR-1 and D1-1 peptides in IFN-c ELISPOT
assay. This suggested processing of the shorter D1-1 epitope from the DR-1 sequence. However, only DR-1-stimulated CD4
or CD3 T cells possessed cytotoxicity against peptide-pulsed autologous DCs and a cancer cell line, that expresses a high
level of cyclin D1. Monoclonal antibody to HLA-DR abrogated the epitope-specific responses of both CD3 and CD4 T cells,
demonstrating class II-mediated killing. Our studies suggest a possible role of CD4 T cells in anti-tumor immunity as
cytotoxic effectors against HLA-DR expressing cancers and provide a rationale for designing peptide vaccines that include
CD4 epitopes.
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Introduction
Cyclin D1 is a key regulatory protein during the progression of
cell cycle through G1 phase. Growth factor stimulation triggers an
increase in cyclin D1 transcript and translation as well as its
assembly into an active cyclin D1/cyclin-dependent kinase (CDK)
4 complex. The active kinase triggers phosphorylation of the
retinoblastoma protein (RB), relieving its transcriptional repressive
activities and its capacity to regulate components of the DNA
replication and G2/M progression [1,2]. It is normally expressed
at low levels in some organs and tissues, but is over-expressed in a
number of human cancers, including mantle cell lymphoma
(MCL), breast cancer, esophageal cancer and non-small cell lung
cancer (NSCLC) [3,4,5,6]. Recent evidence demonstrated the
presence of an alternatively spliced cyclin D1 transcript, called
cyclin D1b. This variant transcript showed a failure of splicing at
the 39 end of exon 4 and as a result, the expected protein product
is altered at its C-terminus. Unlike wild type (WT) cyclin D1a,
cyclin D1b is retained in the nuclus through the cell cycle where its
constitutive expression promotes oncogenic transformation. Stud-
ies from esophageal cancer and murine model of MCL have
suggested that this mutant protein is oncogenic [7,8,9].
These studies suggest that cyclin D1 could be a potential new
target in a wide range of cancers. However, the non-enzymatic
cyclin D1 molecule does not fall into a class of proteins that are
conventionally considered to be targetable by small molecule
inhibitors. In addition, cyclin D1 is an intracellular protein, and
thus a specific antibody (Ab) cannot be directly bound to the
protein. Therefore, generating cytotoxic T lymphocytes (CTLs)
that kill cyclin D1-expressing tumor cells could be a promising
approach. However, there have been limited reports identifying T
cell eitopes derived from cyclin D1 and its potential use for
immunotherapy. Stauss et al. have first reported a HLA-A0201-
binding peptide (cyclin D1 101–109) that induce allogeneic CTLs
in human in vitro [10]. Such allogeneic CTL would be useful for
adoptive immunotherapy involving bone marrow transplant from
partially MHC-mismatched donors. However, active immuno-
therapy in other settings require the peptide vaccines be presented
by host antigen presenting cells (APCs) to T cells to generate anti-
tumor immune responses. Recently, Kondo et al. have reported
that two cyclin D1-derived peptides, including the one from Stauss
group, could induce autologous CD8 CTLs in both healthy donors
and cancer patients [11].
Induction of strong CD8 CTL responses has long been the goal
of most peptide vaccine strategies [12,13]. However, this approach
has achieved limited success in clinical trials [14,15]. A strategy to
include CD4 T cell epitopes in vaccine design, aimed at the helper
function of CD4 T cells in generation of long-lasting memory CD8
T cells, has received promising results [16]. However, the role of
CD4 T cells in directly killing tumor cells or clearing tumors,
independent of CD8 T cells, is less well-studied.
In the present study, we set out to address the questions of
whether including CD4 epitopes enhances CD8 T cell responses
and whether CD4 T cells can be cytotoxic to cancer cells. Our
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protein, that 1) included both CD4 and CD8 epitopes in the same
sequence; 2) could result in processing and presentation of CD8
epitopes; 3) could potentially be presented by multiple class II
molecules, rather than being limited to a single DR type. Due to
the permissive nature of the HLA class II binding pocket, this
latter criteria was possible. Such peptides would therefore be
capable of priming T cells from a larger percentage of the target
population, allowing a vaccine strategy that would address a large
segment of the population.
Materials and Methods
Synthetic peptides
All peptides were purchased and synthesized by Genemed
Synthesis, Inc. (San Antonio, TX). Peptides were sterile and 70%
to 90% pure. The peptides were dissolved in DMSO and diluted in
saline at 5 mg/mL and stored at 280uC. Amino acid sequences and
predicted binding of putative CD4+epitopes to HLA-DRB1
molecules and HLA-A0201 were identified using the predictive
algorithm of the SYFPEITHI database 3 (http://www.syfpeithi.de/)
and RANKPEP (http://bio.dfci.harvard.edu/Tools/rankpep.html).
A CD4 specificity control peptide used for HLA-DR was the JAK-2-
derived DR.B1-binding peptide JAK2-DR (GVCVCGDENILV-
QEF, SYFPEITHI score 24–17; unpublished data). This peptide
induces a CD4 response after multiple stimulations. A CD8
specificity control peptide used for HLA-A0201 was the ewing
sarcoma-derived peptide EW (QLQNPSYDK, RANKPEP score
29; unpublished data).
Cells lines, cytokines and antibodies
The human breast cancer cell line MDA-MB-231 (ATCC
number HTB-26) was used as a target for measuring cytotoxicity
of T cells [10]. The cell line was pre-treated with human
recombinant IFN-c (100 ng/ml) for two days to up-regulate HLA-
DR expression. The cells were washed thoroughly before being
used as targets for IFN-c ELISPOT and
51Cr-release assays. The
haplotype of the cells are: HLA-A0201/0217, B4002/4101,
C0202/1701, DR.B1*0701/1305 and DQ.B1*0202/0301. Hu-
man granulocyte-macrophage colony-stimulating factor (GM-
CSF), interleukin (IL)-1b, IL-4, IL-6, IL-15, tumor necrosis factor
(TNF)-a and prostglandin E2 (PGE2) were purchased from R&D
Systems (Minneapolis, MN). Beta 2-microglobulin (b2-m) and
human IFN-c were purchased from Sigma (St. Louis, MO). The
antibodies used for immunofluorescence assays including mAbs to
human CD3, CD4, CD8, CD56, CD14, CD19, CD83, CD86,
CD11C, HLA-DR and isotype controls were obtained from BD
Biosciences (San Diego, CA). Neutralizing Abs against HLA-A
(clone W6/32), HLA-A2 (clone BB7), HLA-DR (clone L243) and
isotype controls mouse IgG2a (clone F23.2: anti-human Vb8 and
clone KJ1-26: anti-mouse TCR DO-11) were obtained from the
Monoclonal Antibody Facility at MSKCC (New York, NY). Anti-
human cyclin D1 mAb (clone 5D4) was purchased from Beckman
Coulter (Fullerton, CA). Goat F (ab’) 2 anti-mouse Ig’s conjugated
to fluorescent was purchased from Biosource (Camarill, CA). Cell
isolation kits for CD3, CD4, CD8 and CD25 were purchased from
Miltenyi Biotec. (Bergisch Gladbach, Germany).
Flow cytometry and phenotypic analysis
Cyclin D1 expression was measured by intracellular protein
staining using mAb to human cyclin D1 (clone 5D4) and Cytofix/
CytoPerm kit (BD Biosciences), according to the instructions of the
manufacturer. For cell surface staining, cells were incubated with
appropriate mAbs for 30 minutes on ice, washed, and incubated
with secondary antibody reagents when necessary. Analysis was
done on a BD Biosciences FACScan (San Jose, CA) or LSR
(Mountain View, CA).
In vitro stimulation and human T-cell cultures
After informed consent on Memorial Sloan-Kettering Cancer
Center Institutional Review Board approved protocols, peripheral
blood mononuclear cells (PBMC) from HLA-typed healthy donors
were obtained by Ficoll density centrifugation. CD14+ monocytes
were isolated by positive selection using mAb to human CD14
coupled with magnetic beads (Miltenyi Biotec) and were used for
the first stimulation of T cells. The CD14- fraction of PBMC were
used for isolation of CD3, by negative immunomagnetic cell
separation using a pan T cell isolation kit (Miltenyi Biotec). The
purity of the cells was always more than 98%. T cells were
stimulated for 7 days in the presence of RPMI 1640 supplemented
with 5% autologous plasma (AP), 20 ug/mL synthetic peptides,
1 ug/mL b2-m, and 10 ng/mL IL-15. Monocyte-derived den-
dritic cells (DCs) were generated from CD14+ cells, by culturing
the cells in RPMI 1640 medium supplemented with 1% AP,
500 units/mL recombinant IL-4, and 1,000 units/mL GM-CSF.
On days 2 and 4 of incubation, fresh medium with IL-4 and GM-
CSF was either added or replaced half of the culture medium. On
day 5, 20 ug/mL class II peptide was added to the immature DCs.
On day 6, maturation cytokine cocktail was added (IL-4, GM-
CSF, 500 IU/mL IL-1, 1,000 IU/mL IL-6, 10 ng/ml TNF-a,
and 1 ug/mL PGE-2). On day 7 or 8, T cells were re-stimulated
with mature DCs at a 30:1, T: APC ratio, with IL-15. In most
cases, T cells were stimulated 3 times in the same manner, using
either DCs or CD14+ cells as antigen-presenting cells (APCs). A
week after final stimulation, the peptide-specific T cell response
was examined by IFN-c enzyme-linked immunospot (ELISPOT)
assay and the cytotoxicity was tested, by
51chromium (Cr)-release
assay. To deplete the T-reg cell population, we first depleted
CD25+ T cells from CD14- fraction of PBMC, using an mAb to
human CD25 coupled with magnetic beads (Miltenyi Biotec). The
CD25-fraction was subjected to further purification for either
CD3+ or CD4+ fraction. CD3 T cell population was isolated by
negative selection as described above, and CD4 T cell population
was isolated by positive selection using mAb to human CD4-
magnetic beads. This yielded two final populations: CD3+CD25-
or CD4+CD25- T cells.
IFN-c ELISPOT
HA-Multiscreen plates (Millipore) were coated with 100 uL of
mouse anti-human IFN-c antibody (10 Ag/mL; clone 1-D1K;
Mabtech) in PBS, incubated overnight at 4uC, washed with PBS to
remove unbound antibody, and blocked with RPMI 1640/10%
autologous plasma (AP) for 2 h at 37uC. Purified CD4+, CD8+,o r
CD3+ T cells (.98% pure) were plated with either autologous
CD14+ (10:1 E: APC ratio) or autologous DCs (30:1 E: APC
ratio). Various test peptides were added to the wells at 20 ug/mL.
Negative control wells contained APCs and T cells without
peptides or with irrelevant peptides. Phytohemagglutinin (PHA,
Sigma) at a concentration of 20 ug/ml was used as a positive
control for the assay. However, the PHA data was not shown in
the Figs, because PHA induces such a large amount of spots that it
is not possible to plot in the same Figure with the peptide-induced
spots. All conditions were done in triplicate. Blocking experiments
were done in which 50 ug/mL of blocking mAbs or irrelevant
control mAbs were pre-incubated with 10
6 CD14+ or other target
cells for 30 minutes at 37uC and then were presented in the
cultures throughout the incubation period of time. Microtiter
plates were incubated for 20 h at 37uC and then extensively
Cyclin D1-Specific CD4 CTLs
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detection antibody against human IFN-c (2 ug/mL; clone 7-B6-1;
Mabtech) was added. Plates were incubated for an additional 2 h
at 37uC and spot development was done as described [16]. Spot
numbers were automatically determined with the use of a
computer-assisted video image analyzer with KS ELISPOT 4.0
software (Carl Zeiss Vision).
51Chromium release assay
The presence of specific CTLs was measured in a standard 4-
hour chromium release assay as described [17]. Briefly, target cells
alone, or pulsed with 20 ug/mL of synthetic peptides for 2 hours (in
some cases for over night) at 37uC, are labeled with 50 uCi/million
cells of Na2 51CrO4 (NEN Life Science Products, Inc.). After
extensive washing, target cells are incubated with T cells at E: T
ratios ranging from 100:1 to 10:1. All conditions were done in
triplicate. Plates were incubated for 4–5 hrs at 37uC in 5% CO2.
Supernatant fluids were harvested and radioactivity was measured
in a gamma counter. Percentage specific lysis was determined from
the following formula: [(experimental release2spontaneous re-
lease)/(maximum release2spontaneous release)]6100%. Maxi-
mum release was determined by lysis of radiolabeled targets in
1% SDS.
Results
Identification of cyclin D1-derived peptides with high
predicted binding to multiple class II HLA-DR.B1 and
class I HLA-A0201 molecules
Physical linking of T helper and CTL epitopes increases the
magnitude and duration of the CTL response, suggesting that the
presentation of both T helper and CTL epitopes on a single
antigen presenting cell is more efficient than when two epitopes
are presented on different APCs [18]. CD4 T cells help CD8 CTL
by fully activating DCs through the CD40/CD40L signaling as
well as by producing IL-2 and IFN-c [19,20,21]. Therefore, a
peptide combining both CD4 and CD8 epitopes could be
advantageous over the single class I epitope in eliciting effective
immune response for vaccine design. In addition, designing a class
II peptide that contains a class I epitope would allow us to assess
the processing and presentation of the short epitope, assuring that
such a peptide would be a valid vaccine candidate. Because we
recognize that prediction of immunogenic antigens results in both
false negative and false positive sequences, our conclusions would
have to rely ultimately on tests for T cell recognition of the
sequences in vitro. Our approach included the following steps: A)
Prediction of potential epitopes by computer algorithms. This
would serve to limit the number of possible sequence choices; B)
Stimulation of T cells with selected peptides to confirm the
immunogenicity of the epitopes; C) Testing of the response of the
peptide-stimulated T cells against tumor cells that highly express
cyclin D1, to confirm the processing and the presentation of the
epitopes.
We first screened human cyclin D1-a protein sequences using
the BIMAS, SYFPEITHI and RANKPEP algorithms for binding
to HLA-A0201; and a number of peptides were identified that had
predicted high-affinity binding to HLA-A0201. Among them, the
CD8 epitopes with RANKPEP- predicted C-terminal proteasome
cleavage, were selected.
In parallel, the cyclin D1 sequences containing these HLA-
A0201 epitopes but extended for several amino acids in both
directions are further screened in silico for their predicted binding
efficiency to multiple HLA-DR.B1 molecules that are highly
expressed in the Caucasian population. Since the SYFPEITHI
program only predicts binding of 15 amino acid sequences to
HLA-DR molecules, we designed longer peptides by adding
flanking residues in both ends that resulted in overlapping multiple
epitopes for CD4 (15 amino acids) within one sequence. We
designed five HLA-DR.B1-binding peptides; each contains
multiple epitopes for HLA-DR.B1 molecules and one or two
epitopes for HLA-A0201 molecules. The peptide sequences and
their binding prediction for HLA-DR.B1 (SYFPEITHI) and
A0201 molecules (RANKPEP) are shown (Table 1). The putative
HLA-DR.B1-binding peptides are designed as DR-1, 2, 3, 4 and
5. The putative HLA-A0201-binding peptides are named as D1-1,
-2, -3, -4, -5, -6, -7 and 8. As an example, DR-1 peptide (26 amino
acids) spanning cyclin D1-a amino acids 42–67, is predicted to
generate multiple overlapping 15 amino acid epitopes that have a
wide range of binding efficiency to HLA-DR.B1-0101, -0301, -
0401, -0701, 1105 & 1501. An example of two potential 15 amino
acid HLA-DR.B1-binding epitopes within DR-1 peptide is shown
in Table 1. The epitope vsyfkcvqkevlpsm (position 42–56) binds to
multiple HLA-DR.B1 subtypes with scores ranging from 25 to12
out of 35 maximum score. Similarly, the epitope lpsmrkivatwmlev
(position 53–67) shows scores that range of 35–11 binding to
multiple HLA-DR.B1 molecules. There are additional multiple 15
mer fragments that were predicted to be potential epitopes for
HLA-DR.B1 molecule by SYFPEITHI algorithm as well (data not
shown). In addition, two HLA-A0201-binding, 9 mer peptides are
embedded within the DR-1 peptide; the D1-1 peptide spanning
sequences 59–67 and the D1-2 spanning sequences 52–60,
displayed binding scores of 85 and 59, respectively, by RANKPEP
prediction. Importantly, the HLA-A0201-binding peptides are
predictedto be cleaved at their C-terminals, suggesting a possibility
of being processed by the proteosome. Such multi-epitope peptides
should offer an advantage of inducing simultaneously robust
CD4+ and CD8+ T-cell responses.
Multiple cyclin D1-derived peptides induced peptide-
specific CD3 T cell responses
Web-based predictive algorithms are only 70% reliable in
identifying peptide epitopes capable of stimulating T cells [22].
Therefore, in vitro stimulation assays are necessary to confirm those
peptides that can stimulate T cells. CD3 T cells from healthy
donors were initially used as effectors because they could respond
to both class I and II peptides. The cells were stimulated with
peptide-loaded CD14+ positive cells or autologous DCs for three
rounds and the IFN-c secretion was measured in ELISPOT assay.
All of the HLA-DR.B1 peptides, except for DR-2, could induce
peptide-specific CD4+ responses (Fig. 1A–E). However, DR-1
consistently induced the best response in a variety of HLA-DR.B1
settings, reproduced multiple times in more than 10 healthy
donors, each with different HLADR.B1 haplotypes.
More importantly, CD3 T cells stimulated with DR-1 peptide
also reacted to HLA-A0201-restricted class I peptide D1-1. This
suggested that the D1-1 peptide might be processed and presented
to CD8 T cells. The other HLA-A0201-restricted peptides
imbedded within DR-1 (D1-2), DR-2 (D1-3 and D1-4), DR-3
(D1-7), DR-4 (D1-5) and DR-5 (D1-6 and D1-8) were not reactive
with the CD3 T cells stimulated with their respective long
peptides, although the epitopes were predicted to be processed in
C-terminus. Since the DR-1 peptide offered the possibility of
inducing simultaneously a robust CD4+ and CD8+ T-cell
response against DR-1 and D1-1 peptides, we were interested in
further pursuing this peptide as a potential vaccine candidate. To
confirm that the D1-1 peptide was immunogenic alone, CD3 T
cells were stimulated with D1-1 peptide and it induced strong
peptide-specific IFN-c secretion (Fig. 1F).
Cyclin D1-Specific CD4 CTLs
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Using CD3 T cells as effectors allowed us to simultaneously
measure both class II and class I-restricted T cell responses, if the
class I peptides were processed from the longer class II sequences.
In addition, the presence of CD4 T cells should improve CD8 T
cell response, as demonstrated before in other systems
[23,24,25,26]. To further clarify the role of CD4 and CD8 T
cells in the mixed CD3 T cell responses specific for DR-1 and D1-
1 peptides, we next purified CD3, CD4 and CD8 T cell
populations from healthy donors (HLA-A0201 positive with
various HLA-DR.B1 haplotypes) and compared their responses
against the stimulating peptides. When CD3 and CD4 T cells from
the same donor were stimulated with the DR-1 peptide, CD3 T
cells showed a stronger peptide-specific response (Fig. 2A). On the
other hand, when CD3 and CD8 T cells from the same donor
were stimulated with the D1-1 short peptide, CD3 T cells showed
a far better peptide-specific response than CD8 T cells alone
(Fig. 2B). This suggests that presence of CD4 T cells may help
CD8 T cells. To confirm that the D1-1-specific response by CD3
T cells is not mediated by CD4 T cells, we also stimulated CD4 T
cells with D1-1 and found no response could be generated (data
not shown). These results confirmed our previous observation that
CD3 T cells act as better effector cells than CD8 T cells alone in
the induction of MHC class I peptide-specific response, most likely
getting help from CD4 T cells (unpublished data).
Cyclin D1-DR-1 peptide induced HLA-DR.B1-restricted
cytotoxic CD4 T cells
Peptides that are presented on the surface of target cells bound to
eitherHLAclass I orclass IImoleculesmustfirstbe processedeither
in the cytosol for class I peptides or in endocytic vesicles for class II
peptides. Because the peptides derived from cyclin D1 were
identified first by computer algorithms, it was necessary to
determine whether these peptides were properly processed from
the cyclin D1 protein and presented in the context of HLA
molecules. Only the peptide fragments that are presented on the
tumor cell surface can be recognized by peptide-specific T cells. We
therefore tested if the DR-1 and D1-1 peptide-stimulated CD3 T
cells were cytotoxic to tumor cells highly expressing cyclin D1. A
HLA-A0201 positive human breast cancer cell line MDA-MB-231
was chosen because of its high expression of cyclin D1 [10]. We
performed intracellular protein staining and confirmed the high
level expression of the cyclin D1 compared to autologous mature
DCs (Fig. 3A). This result is in agreement with reports from others
that cyclin D1 is expressed at low level in normal tissues [27]. In
addition, mature DCs show uptake of
51Cr, in contrast to resting
lymphocytes, and therefore, could serveas a suitable target for
51Cr-
release assay. The expression of HLA-A2 and DR was assessed by
flow cytometry analysis followed by specific mAb staining. MDA-
MB-231 cells express high levels of HLA-A2 molecule (Fig. 3B),
which was slightly up-regulated by IFN-c treatment. In contrast, the
HLA-DR expression was mostly negative on MDA-MB-231 cells,
but was significantly up-regulated by IFN-c treatment (Fig. 3C).
The IFN-c pre-treatment did not alter the cyclin D1 expression on
theMDA-MB-231cells(datanot shown) and thereforeruledout the
possibility that the killing of the cells was due to the change of the
cyclin D1 expression. CD3 T cells from different donors that were
stimulated with DR-1, consistently killed the autologous DCs pulsed
with DR-1peptide (10 out of 12 experiments), but not with the D1-1
peptide. Representative data from a donor (HLA-A0201+) is shown
(Fig. 4A).
Table 1. Peptides from human cyclin D1-a that are predicted to bind to HLA-DR.B1 and embedded short peptides (in italics) that
bind to HLA-A0201 molecules.
Name Sequences Position Score*
DR-1 VSYFKCVQKEVLPSMRKIVATWMLEV 42–67
VSYFKCVQKEVLPSM 42–56 *HLA-DR.B1: 25–12
LPSMRKIVATWMLEV 53–67 HLA-DR.B1: 35–11
D1-1 IVATWMLEV 59–67 *HLA-A0201: 80
D1-2 VLPSMRKIV 52–60 HLA-A0201: 67
DR-2 AQTFVALCATDVKFISNPPSMVAAGSVV 182–209
AQTFVALCATDVKFI 182–196 HLA-DR.B1: 36–16
ATDVKFISNPPSMVA 190–204 HLA-DR.B1: 26–18
D1-3 FVALCATDV 185–193 HLA-A0201: 61
D1-4 SMVAAGSVV 201–209 HLA-A0201: 75
DR-3 LLLVNKLKWNLAAMT 142–156 HLA-DR.B1: 36–20
D1-7 LVNKLKWNL 144–152 HLA-A0201: 48
DR-4 MNYLDRFLSLEPVKK 82–96 HLA-DR.B1: 34–12
D1-5 NYLDRFLSL 83–91 HLA-A0201: 46
DR-5 VQGLNLRSPNNFLSYYR 212–228
VQGLNLRSPNNFLSY 212–226 HLA-DR.B1: 24–3
GLNLRSPNNFLSYYR 214–228 HLA-DR.B1: 24–13
D1-6 NLRSPNNFL 216–224 HLA-A0201: 51
D1-8 SPNNFLSY 219–226 HLA-A0201: 28
*SYFPEITHI prediction software was used for HLA-DR.B1-binding prediction. Each epitope has different binding affinity to various DR.B1 subtypes, which was
summarized as the range of binding scores. RANKPEP prediction software was used for HLA-A0201 prediction and C-terminal cleavage.
doi:10.1371/journal.pone.0006730.t001
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6730Figure 1. IFN-c ELISPOT by CD3 T cells stimulated with cyclin D1 peptides. CD3 T cells from healthy donors with HLA-A0201 and various
HLA-DR.B1 haplotypes were stimulated three times with human cyclin D1-derived peptides DR-1 (A), DR-2 (B), DR-3 (C), DR-4 (D), DR-5 (E) or D1-1 (F),
as described in the Materials and Methods. Stimulated CD3 T cells were challenged in IFN-c ELISPOT assay with the stimulating HLA-DR.B1 class II
peptides and the HLA-A0201 class I peptides that were imbedded within the class II peptides, as indicated. Controls are: un-pulsed CD14+ cells,
irrelevant peptides JAK2-DR for HLA-DR.B1 and EW for HLA-A0201. The results represent the average spots in triplicate cultures plus/minus standard
deviation (SD). The figures show one representative experiment from multiple similar experiments.
doi:10.1371/journal.pone.0006730.g001
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peptide did not kill the DCs pulsed with the D1-1 short peptide in
multiple donors with HLA-A0201 haplotype (data not shown).
This was surprising, because the D1-1 peptide-stimulated CD3 T
cells consistently responded to D-1- that was pulsed onto
autologous APCs in IFN-c ELISPOT assay. This suggested that
DR-1-specific CD4 T cells might be the killer cells in the bulk
CD3 T cells. To confirm if the DR-1-induced cytotoxicity was
indeed mediated by CD4 T cells, we next used purified CD4 T
cells as effectors. We found that the DR-1 stimulated CD4 T cells
were also able to kill autologous DCs pulsed with DR-1 peptide,
but not un-pulsed DCs or DCs pulsed with irrelevant DR1-
binding peptide JAK2-DR. More importantly, the CD4 T cells
also killed IFN-c-pretreated MDA-MB-231 cell line, as shown in
Fig. 4B (from a donor with HLA-A0201+ and HLA-DR.B1-
0701+), but not the IFN-c-untreated cells, indicating HLA-DR-
Figure 2. IFN-c ELISPOT by CD3, CD4 or CD8 T cells stimulated
with cyclin D1-DR1 or D1-1 peptides. (A) CD3 or CD4 T cells from a
healthy donor (HLA-A0201 and DR.B1 0104/1104) were stimulated twice
with human cyclin D1-derived peptides DR-1, as described in the
Materials and Methods. (B) CD3 or CD8 T cells from a healthy donor
(HLA-A0201 and HLA-DR.B1 0801/0901) were stimulated three times
with human cyclin D1-derived peptides D1-1. Stimulated T cells were
challenged in IFN-c ELISPOT assay with the stimulating peptide DR-1 or
D1-1. The controls are: un-pulsed CD14+ cell as APCs, irrelevant
peptides JAK2-DR for HLA-DR.B1 and EW for HLA-A0201. The results
represent the average spots in triplicate cultures +/2 SD. The figures
show one representative data from multiple similar experiments.
doi:10.1371/journal.pone.0006730.g002
Figure 3. The expression of cyclin D1 and HLA molecules
determined by flow cytometry. Cyclin D1 expression on mature DCs
and MDA-MB-231 cell line was determined by intracellular protein staining
using Cytofix/Cytoperm kit (A). The cells were stained with the mAb to
human cyclin D1, or isotype control mouse IgG1, then were followed by the
secondary antibody goat anti-mouse Ig (Fab)2 conjugated to FITC. Solid
and dash lines are the DCs and MDA-MB-231 cells stained with isotype
controls, respectively. The dash-dot-dash and dotted lines show the cyclin
D1 expression on DCs and MDA-MB-231 cells, respectively. HLA-A0201 (B)
o rH L A - D R( C )e x p r e s s i o no nM B A - M B - 2 3 1w a sd e t e r m i n e db ys u r f a c e
staining of the cells with mAbs to HLA-A2 or HLA-DR, before and after
treatment with IFN-c. Dash and solid lines show the isotype controls before
and after IFN-c treatment, respectively. The dash-dot-dash and dot lines
show HLA-A0201 expression before or after IFN-c treatment (B). Similarly,
the dash and solid lines show the isotype controls staining before and after
IFN-c treatment; the dot and dash-dot-dash lines show the HLA-DR
expression before or after IFN-c treatment (C).
doi:10.1371/journal.pone.0006730.g003
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repeated in six separate donors in nine experiments and were
reproducible 7 times. To confirm the CD4 T cell responses are
mediated via HLA- DR.B1, we next performed the blocking
experiments using anti-HLA-DR mAb in
51CR-release assays.
The mAb to HLA-DR significantly abrogated the DR-1 peptide-
induced cytotoxicity of CD4 T cells against both DCs pulsed with
DR-1 peptide and MDA-MB-231 cells (Fig. 4C). These results
demonstrated that CD4 T cells recognized DR-1 epitope and are
able to kill the cells expressing the epitope. On the contrary, D1-1
short peptide-stimulated CD3 or CD8 T cells did not kill MDA-
MB-231, nor the other two HLA-A0201+ MCL cell lines, NCEB1
and Jeko, that also express high levels of cyclin D1 (data not
shown). These results indicated, as suggested earlier, that the D1-1
epitope may not be processed in the target tumor cells, or CD8 T
cells have a low-avidity for the epitope (Fig. 2B), which results in
inefficient killing.
To investigate if depletion of T-regs could enhance the
recognition of naturally processed epitopes in tumor cells by
CD4 T cells, we compared DR-1-specific response between
CD4+CD25+ T cells and CD4+CD25-T cells from the same
donors in the IFN-c ELISPOT assay. IFN-c secretion between two
populations were similar (Fig. 5). The mAb to HLA-DR abrogated
the response to DR-1 peptide presented by autologous DCs and
more importantly, the response to MDA-MB-231 cells. The results
further supported the data from (Fig. 4C) that the DR-1 peptide can
induce HLA-DR-restricted CD4 T cell response.
Figure 4. Induction of cytotoxicity by CD3 and CD4 T cells
stimulated with DR-1 peptide. CD3 T cells from a HLA-A0201 donor
were stimulated with DR-1 peptide for three times, and the cytotoxicity
of the cells was measured by
51Cr-release assay against autologous DCs
pulsed with or without indicated peptides (A). Similarly, the purified
CD4 T cells from a HLA-A0201 and HLA-DR.B1-0701 donor was
stimulated with DR-1 peptide and their cytotoxicity was measured by
51C-release assay against autologous DCs pulsed with or without
indicated peptides, and MDA-MB-231 cell line (B). Antibody blocking
was performed by pre-incubating target cells with anti-HLA-DR and
isotype-matching irrelevant mAb (50 ug/ml) for 30 minutes before
adding to the co-culture with effector cells at an E: T ratio of 100:1 (C).
The figure shows representative data from multiple similar experiments.
All data points are the mean of triplicate microwell cultures.
doi:10.1371/journal.pone.0006730.g004
Figure 5. IFN-c ELISPOT by CD4+CD25+ and CD4+CD25- T cells
stimulated with cyclin D1-DR1 peptide. CD4+ (A) or CD4+CD25- T
cells (B) from healthy donors were stimulated three times with DR-1
peptide, as described in the Materials and Methods. Stimulated T cells
were challenged in IFN-c ELISPOT assay with the stimulating peptide
DR-1 or controls on CD14+ cells, B cells or MDA-MB-231 cells. Antibody
blocking was performed by adding the anti-HLA-DR and isotype control
mAb (50 ug/ml) in the cultures. The controls are: CD4 T cells cultures
with un-pulsed CD14+ cells, irrelevant peptides JAK2-DR for HLA-DR.B1,
and allogenic B cells from a donor who has matching HLA-DR.B1*0701
with MDA-MB-231 cells. The results represent the average spots in
triplicate cultures +/2 SD. The figures show one representative data
from three similar experiments.
doi:10.1371/journal.pone.0006730.g005
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Increasing evidence has shown that vaccines with longer peptide
sequences may perform better than minimal MHC class I binding
peptide vaccines in anti-tumor immunity, in both mouse models
and human trials [16,18,24]. Several mechanisms may contribute
to improved efficacy. Inclusion of CD4 T cell epitopes in peptide
vaccines help to induce and sustain effective CD8 T cell responses
[28,29]; longer peptides can be taken up and processed by DCs in
vivo to induce effective CD8 T cell response, avoiding the induction
of transient or tolerant CD8 responses if short peptides bind to less
efficient APCs, such as B and T cells [30,31]; there may be extra-
cellular proteases known to trim peptides and therefore, short
peptides may be rapidly biodegraded, while larger peptides are
relatively protected and may benefit from additional extra-cellular
processing [32,33]. Finally, CD4 T cells, in some cases,
themselves, may be cytotoxic to tumor cells.
In an attempt to improve vaccine efficacy, we designed long
peptides from human cyclin D1-a protein that contain overlapping
multiple epitopes of HLA class I and II epitopes. These peptides
were intended to induce simultaneous CD4 and CD8 T cell
responses, as shown for other combinations of T cell epitopes [25].
Importantly, this approach also allow us to measure if the CD8
epitopes are processed and presented. This is crucial for an
effective vaccine therapy. In our initial screening of T cell response
by IFN-c ELISPOT assay, we found that four out of five long
peptides we designed, based on the MHC-binding algorithms,
induced strong CD3 T cell responses specific for the stimulating
peptides. However, only one class II peptide, DR-1, induced CD3
T cells response against both DR-1 peptide and a short peptide
D1-1, imbedded within the DR-1 sequence, suggesting that this
CD4 epitope might be processed into the CD8 epitope. Although
the other short peptides (D1-2 to D1-8) were predicted to be
cleaved at C-terminal, none of them appeared to be processed, as
assessed by recognition of these short peptides by CD3 T cells that
have been stimulated with their respective long peptides. These
results indicate that the CD8 epitopes predicted by MHC class I-
binding and C-terminal cleavage algorithms are usually immuno-
genic, but not necessarily processed and presented appropriately.
Therefore, our studies emphasize the importance of the verifica-
tion of the function of the peptide sequences in vaccines, identified
following epitope prediction algorithms, for processing and
presentation by both host APCs and tumor cells.
To our surprise, CD3 T cells stimulated with DR-1 peptide not
only induced IFN-c secretion, but also killed the DCs pulsed with
DR-1 peptide. In contrast, the D1-1 short peptide induced a
strong peptide-specific response in IFN-c ELISPOT assay,
however, the peptide failed to induce cytotoxicity of either CD3
or CD8 T cells against peptide-pulsed autologous DCs and several
tumor cells lines that highly express cyclin D-1. It is possible that
although D1-1 peptide could activate CD8 T cells to produce IFN-
c, after three rounds of in vitro stimulations, they may have not
differentiated into cytotoxic effector T cells. It is also possible that
the frequency of the D1-1-specific CD8 T cells with high avidity
for the epitope from bulk cultures may not be high enough, as
shown in an analogous system by Stauss et al. [10]. In their study,
only the high-avidity CTL clones, generated by limiting dilution,
could kill the cyclin D1-expressing MDA-MB-231 cells, while the
CTL clone with low-avidity failed to do so. In earlier studies
(unpublished), cyclin D1 peptides 101–109 [10] and 228–236 [11]
were identified because of their high binding avidity to HLA-
A0201, predicted by computer algorithms. Peptide 228 was highly
immunogenic measured by IFN-c secretion, however, the peptides
could not induce cytotoxicity in our system after three to four
rounds of stimulation. Collectively, these studies suggest that the
repetitive stimulations may be necessary to obtain high-avidity T
cell clones in vitro.
Our studies support a strong helper CD4 T cell activity by
showing a superior response of CD3 T cells than CD8 T cells
against the same HLA class I peptide. We did not further
investigate the mechanisms of this well-documented phenomenon.
Rather, we focused on exploring a new possibility of inducing
cytotoxic CD4 T cells directed at protein cyclin D1. To date, in
vivo studies have shown that CD4 T cells can clear MHC class II-
negative tumors via IFN-c, which activates and induces tumor-
icidal macrophages. A recent study has provided a clear evidence
that CD4 T cells can be more powerful anti-tumor effectors than
CD 8 T cells, in a mouse model [34]. The authors suggested that
interactions between CD4 T cells and NK cells or macrophages
may have contributed to the anti-tumor immunity of the CD4 T
cells. Moreover, Hunder et al. have reported that infusing NY-
ESO-1-specific CD4 T cells, that were isolated and expanded in
vitro from a patient with metastatic melanoma, induced complete
tumor regression [35]. Although no definitive mechanisms are
provided for the therapeutic efficacy of CD4 T cell in this case, the
study demonstrated the important role of CD4 T cells in anti-
tumor immunity in a patient with cancer. The direct cytotoxicity
of CD4 T cells against tumor has not been firmly established,
however, studies have shown that cyotoxic CD4 T cells can be
induced that play an important role in clearance of pathogens,
such as EBV and CMV infections [36,37,38]. In our studies, cyclin
D1-DR1 peptide could prime both CD3 and CD4 T cells from
donors with a broad range of HLA-DR.B1 haplotypes. More
interestingly, the CD4 T cells from the HLA-DR.B1-matched
donors are also able to kill the peptide-pulsed autologous DCs and
more importantly, a tumor cell line, MDA-MB-231, expressing a
high level of cyclin D1. The anti-HLA-DR antibody abrogated
both the IFN-c secretion and the cytotoxicity, confirming that the
DR-1 peptide could induce a HLA-DR-mediated cytotoxic CD4
T cell response. Our studies provided the proof of concept that
CD4 T cells can be cytotoxic against MHC class II positive tumor
cells. This mechanism might be particularly important when
tumor cells escape CD8 T cell attack by alteration of MHC class I
expression; these ‘‘immune escape variants’’, are seen commonly
in tumor cells [39], Although some tumor cells do not express
MHC class II molecules, IFN-c secretion by T cells and NK cells
in an inflammatory environment in tumor sites could up-regulate
MHC class II expression and render tumor cells susceptible to
CD4 T cell killing. Therefore, CD4-based treatment in vaccine
strategy should be investigated further for developing more
effective anti-tumor immunotherapy.
The impact of the CD4+CD25 T-regs in anti-tumor immunity
has been widely reported in animal models [40,41]. Although the
effects of T-reg depletion remains to be determined in patients
with cancers, recent in vitro studies have shown that the depletion
of T-regs enhances vaccine-induced T cell immune responses in
various cancers [42,43,44,45]. Of particular interest is that the
depletion of T-regs enhances the recognition of naturally
processed tumor antigens, by eliminating the inhibition of T-regs
on high-avidity T cells specific for tumor Ags, such as NY-ESO-1,
in cancer patients [43,44,45]. We investigated the role of T-regs in
the T cell response generated to the cyclin D1-derived peptides.
No significant differences in CD4 T cell response against HLA-DR
peptide DR-1 (Fig. 5), nor CD8 T cell responses against HLA-A2-
specific peptide D1-1 (data not shown) were seen.
In conclusion, we identified a human cyclin D1-derived CD4
epitope potentially capable of interacting with multiple HLA-DR
molecules, which provides priming and helper capacity in multiple
Cyclin D1-Specific CD4 CTLs
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cytotoxicity of CD4 T cells against tumor cells highly expressing
cyclin D1 in the context of HLA-DR.B1 molecules. Considering
the wide distribution of cyclin D1 in tumor cells, generation of
specific CD4 CTLs, might add therapeutic activity in HLA-DR-
expressing cancer cells.
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